These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 32141173)
1. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173 [TBL] [Abstract][Full Text] [Related]
2. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial. Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100 [TBL] [Abstract][Full Text] [Related]
3. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221 [TBL] [Abstract][Full Text] [Related]
4. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Chung JW; Lee JH; Jung HY; Yun SC; Oh TH; Choi KD; Song HJ; Lee GH; Kim JH Helicobacter; 2011 Aug; 16(4):289-94. PubMed ID: 21762268 [TBL] [Abstract][Full Text] [Related]
5. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication. Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386 [TBL] [Abstract][Full Text] [Related]
6. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial. Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS; Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320 [TBL] [Abstract][Full Text] [Related]
7. Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial. Ding YM; Zhang QM; Li RL; Han ZX; Zhao Q; Xu LD; Wang KY; Nan XP; Duan M; Zeng SY; Kong QZ; Wang H; Wu XQ; Zhang N; Li YQ; Zuo XL; Li YY Helicobacter; 2024; 29(4):e13121. PubMed ID: 39097924 [TBL] [Abstract][Full Text] [Related]
8. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915 [TBL] [Abstract][Full Text] [Related]
9. Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days. Knigge K; Kelly C; Peterson WL; Fennerty MB Aliment Pharmacol Ther; 1999 Mar; 13(3):323-6. PubMed ID: 10102965 [TBL] [Abstract][Full Text] [Related]
10. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice. Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Lee SK; Lee SW; Park JY; Kwon BS; Kim SY; Hyun JJ; Kim JH; Jung SW; Koo JS; Yim HJ; Choi JH Helicobacter; 2011 Oct; 16(5):410-4. PubMed ID: 21923688 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Tetracycline Three Times Daily was Comparable to That of Four Times Daily for Helicobacter pylori Rescue Treatment: A Multicenter, Noninferiority, Randomized Controlled Trial. Han Z; Zhang Q; Mirza IA; Ding Y; Nan X; Zhao Q; Li R; Xu L; Zhang N; Duan M; Zeng S; Kong Q; Zhang W; Wang H; Wu X; Zuo X; Li Y; Li Y Helicobacter; 2024; 29(3):e13102. PubMed ID: 38873902 [TBL] [Abstract][Full Text] [Related]
13. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice. Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857 [TBL] [Abstract][Full Text] [Related]
14. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication. Song ZQ; Zhou LY J Dig Dis; 2016 Apr; 17(4):260-7. PubMed ID: 26946480 [TBL] [Abstract][Full Text] [Related]
15. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication]. Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124 [TBL] [Abstract][Full Text] [Related]
17. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Kim SJ; Chung JW; Woo HS; Kim SY; Kim JH; Kim YJ; Kim KO; Kwon KA; Park DK World J Gastroenterol; 2019 Dec; 25(46):6790-6798. PubMed ID: 31857780 [TBL] [Abstract][Full Text] [Related]
18. Second-line bismuth-containing quadruple therapy for Kim SE; Park MI; Park SJ; Moon W; Kim JH; Jung K; Kim HK; Lee YD World J Gastroenterol; 2017 Feb; 23(6):1059-1066. PubMed ID: 28246480 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004 [TBL] [Abstract][Full Text] [Related]